


ABSTRACT

This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I:




I


5

where:


R¹ is a group represented by formula (A), (B) or (C);



(A)



(B)



(C)

10

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.